Multimodal hyperbranched polymers for simultaneous imaging and drug delivery for targeted prostate cancer theranostics

Fuchs, Adrian V., Pearce, Amanda K., Tse, Brian W. C., Whittaker, Andrew K., Russell, Pamela J. and Thurecht, Kristofer J. (2014). Multimodal hyperbranched polymers for simultaneous imaging and drug delivery for targeted prostate cancer theranostics. In: ACS 2014: 247th American Chemical Society National Meeting & Exposition, Dallas, TX, USA, (). 16-20 March, 2014.

Author Fuchs, Adrian V.
Pearce, Amanda K.
Tse, Brian W. C.
Whittaker, Andrew K.
Russell, Pamela J.
Thurecht, Kristofer J.
Title of paper Multimodal hyperbranched polymers for simultaneous imaging and drug delivery for targeted prostate cancer theranostics
Conference name ACS 2014: 247th American Chemical Society National Meeting & Exposition
Conference location Dallas, TX, USA
Conference dates 16-20 March, 2014
Journal name Abstracts of Papers of the American Chemical Society
Place of Publication Washington, DC, United States
Publisher American Chemical Society
Publication Year 2014
Sub-type Published abstract
Open Access Status
ISSN 0065-7727
Volume 247
Total pages 1
Language eng
Formatted Abstract/Summary
The need to simultaneously target and image prostate cancer while providing the means to site-selectively deliver a therapeutic is currently at the forefront of detecting and treating many cancers. This theranostic approach is realised through the use of hyberbranced polymer (HBP) systems whereby the multi-armed polymers allow the incorporation of various modalities within the one system.

As imaging modalities, we describe the synthesis of hyperbranched copolymers containing 2,2,2-trifluoroethyl acrylate and a near infrared dye providing the capability for 19F MRI and optical (fluorescence) imaging. Targeting of prostate cancer is focussed on ligands that bind prostate specific membrane antigen (PSMA) and is achieved by comparing three different targeting ligands including a small molecule urea glutamate derivative, a polypeptide and a monoclonal antibody (MAb J591). Targeting and imaging efficiencies were tested both in vitro and in vivo using PSMA positive prostate cancer cells and xenografts. Drug delivery was achieved through a hydrazone linked moiety which was demonstrated to be released at pH 5.5.
Q-Index Code EX
Q-Index Status Provisional Code
Institutional Status UQ

 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Google Scholar Search Google Scholar
Created: Wed, 30 Jul 2014, 09:30:20 EST by Adrian Fuchs on behalf of Aust Institute for Bioengineering & Nanotechnology